Glycopyrrolate
Brand names: Cuvposa, Glycopyrrolate
At a glance
- Medicare prescriptions, 2024
- 131,466
- Medicare drug cost
- $5.7M
- Average cost per prescription
- $43.44
- Clinicians who prescribed it
- 5,986
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
CUVPOSA is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy).
From the FDA-approved prescribing information (label dated December 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Internal Medicine 19.8%
- Family Medicine 17.9%
- Nurse Practitioners 13.4%
- Psychiatry 9.9%
- Neurology 7.9%
- Psychiatric Nurse Practitioners 5.2%
- Gastroenterology 5.1%
- Physician Assistants 4.5%
- General Practice 2.3%
- Geriatric Medicine 2.2%
- ENT (Otolaryngology) 1.7%
- Dermatology 1.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 9% from 2019 to 2024.
Biggest change by state since 2019
- Pennsylvania +18%
- New York +15%
- Puerto Rico +12%
- Indiana +11%
- Michigan +11%
- Kentucky (smallest change) −13%
- Tennessee (smallest change) −9%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | white round tablet, 8 mm, scored to split in 2 | K 400 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $365,029 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Intra-sana Laboratories $365,029
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
11 recalls since 2020
- Jul 2026 · Fresenius Kabi USA, LLC · Class II
Presence of Particulate Matter: Hair was found in product - Jul 2026 · Precision Dose Inc. · Class II
Failed Impurities/Degradation Specifications - Dec 2025 · Novadoz Pharmaceuticals LLC · Class III
Failed Impurities/Degradation Specifications - Jun 2023 · Hf Acquisition Co LLC · Class III
Labeling: Label Mix-up - May 2023 · Aurolife Pharma, LLC · Class III
Failed Impurities/Degradation Specifications - Feb 2023 · Accord Healthcare, Inc. · Class II
CGMP Deviations: recalling drug products following an FDA inspection. - Dec 2022 · Avkare LLC · Class II
Failed impurities/degradation specifications: Out of specification for unknown impurities. - Dec 2022 · Aurolife Pharma, LLC · Class II
Failed Impurities/Degradation Specifications
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.